Cypress Wealth Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cypress Wealth Services’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$200K	Hold	20,000	–	–	0.02%	413
2026 Q1	$190K	Hold	20,000	–	–	0.03%	384
2025 Q4	$156K	Hold	20,000	–	–	0.02%	379
2025 Q3	$152K	Hold	20,000	–	–	0.02%	341
2025 Q2	$179K	Hold	20,000	–	–	0.03%	307
2025 Q1	$150K	Hold	20,000	–	–	0.03%	276
2024 Q4	$150K	Hold	20,000	–	–	0.03%	272
2024 Q3	$152K	Hold	20,000	–	–	0.03%	275
2024 Q2	$124K	Hold	20,000	–	–	0.03%	253
2024 Q1	$102K	Hold	20,000	–	–	0.02%	257
2023 Q4	$120K	Hold	20,000	–	–	0.03%	240
2023 Q3	$142K	Hold	20,000	–	–	0.04%	231
2023 Q2	$144K	Hold	20,000	–	–	0.04%	242
2023 Q1	$167K	Hold	20,000	–	–	0.05%	237
2022 Q4	$230K	Hold	20,000	–	–	0.07%	209
2022 Q3	$273K	Hold	20,000	–	–	0.09%	179
2022 Q2	$212K	Hold	20,000	–	–	0.07%	209
2022 Q1	$325K	Hold	20,000	–	–	0.09%	167
2021 Q4	$277K	Hold	20,000	–	–	0.08%	182
2021 Q3	$287K	Hold	20,000	–	–	0.09%	176
2021 Q2	$316K	Hold	20,000	–	–	0.09%	191
2021 Q1	$203K	Hold	20,000	–	–	0.04%	280
2020 Q4	$149K	Buy	+20,000	New	+$103K	0.03%	280
2020 Q3	–	Sell	-10,000	Closed	-$42.9K	–	283
2020 Q2	$48K	Hold	10,000	–	–	0.01%	272
2020 Q1	$20K	Buy	+10,000	New	+$27.5K	0.01%	246

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Cypress Wealth Services's BCRX Position: Q2 2026 in Review

Cypress Wealth Services held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 20,000 shares worth $200K. The position accounts for 0.02% of the portfolio, ranked #413.

Cypress Wealth Services first reported a position in BCRX in Q1 2020 and has held it in 25 quarters since. The position peaked at $325K in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Cypress Wealth Services held 20,000 shares of BioCryst Pharmaceuticals worth $200K as of Q2 2026.
Cypress Wealth Services left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up 0.02% of Cypress Wealth Services's portfolio in Q2 2026, its #413 holding.
Cypress Wealth Services first reported a position in BioCryst Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
Cypress Wealth Services's BioCryst Pharmaceuticals position peaked at $325K in Q1 2022.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Cypress Wealth Services's 13F filing for Q2 2026, filed 13 Jul 2026.